Extended Data Fig. 5: Intermediate co-expressor (IC) ‘Hybrid’ states are significantly enriched in post-CTX samples.
From: Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
a) Top panel, heatmap showing the expression of gene signatures derived from single cell analyses that define distinct Classical (scClassical), Basal (scBasal) and Intermediate co-expressor (IC) cell phenotypes. Patient samples are ordered according to increasing scBasal ssGSEA enrichment scores. Bottom panel, bar charts showing the percent tumor enrichment of GATA6/CYP3A/KRT17 cell populations as determined by multiplexed IF. Patient samples in top panel and bottom panel are identical and similarly ordered. A LOESS regression line has been added to each bar plot. b) Box plots showing the enrichment of scClassical, scBasal and scIC signature scores in chemo-naïve and post-CTX patient samples. Sample numbers (n) shown at the bottom of each plot. Two-sided Welch’s t-test was performed to determine significance between treatment groups. Welch’s P-values were not corrected for multiple testing. Two-sided Friedman rank sum test was performed to determined significance between signature score in indicated treatment group. Friedman P-values were adjusted for multiple testing. Boxplots show the median (line), the interquartile range (IQR) between the 25th and 75th percentiles (box) and 1.5× the IQR ± the upper and lower quartiles. c) Bar stat plots showing the number of GATA6/KRT17/CYP3A ‘hybrid’ cells observed (n) in Moffitt subtypes Basal (n = 20) and Classical (n = 27). A Pearson χ2-test of independence (two-sided) is provided at the top of each plot and P-values from a one sample proportions test (two-sided) are displayed on the top of each bar. P-values were not adjusted for multiple testing.
